Latest articles and price-sensitive announcements with AI sentiment classification.
Highlights Pro Medicus stands out as a specialist in advanced medical imaging software used by major hospital networks. Its contract-driven model continues to reinforce a strong, recurring revenue structure within global healthcare systems. The company remains a standout name within the ASX mid cap healthcare technology space. Pro Medicus remains a leading healthcare technology name, supported b...
Highlights Pro Medicus has announced a strategic investment and commercial partnership with EchoIQ. The collaboration aims to expand artificial intelligence capabilities within cardiac imaging. The agreement strengthens Pro Medicus' broader strategy of integrating AI into clinical imaging workflows. Pro Medicus Ltd (ASX:PME) has strengthened its artificial intelligence ambitions after announcing a strategic investment and commercial partnership with EchoIQ Ltd...
Highlights Pro Medicus continues expanding its healthcare AI ecosystem through strategic partnerships. Several ASX-listed medical technology companies have emerged as potential strategic fits. Cardiology, diagnostic imaging and medical AI remain key areas of industry innovation. Pro Medicus Ltd (ASX:PME) has attracted renewed market attention following its recent investment in EchoIQ, adding to its earlier backing of 4DMedical. The latest move has prompted bro...
This small-ticket transaction matters far more than its size suggests. The post Pro Medicus just struck a revolutionary AI cardiology deal. Here's why that matters appeared first on The Motley Fool Australia.
Highlights Diagnostics software and recurring revenue are reshaping how healthcare shares are being assessed across the Australian market. Pro Medicus (ASX:PME), CSL (ASX:CSL), ResMed (ASX:RMD), Telix Pharmaceuticals (ASX:TLX) and 4DMedical (ASX:4DX) are highlighting the growing importance of company-specific execution. Healthcare sector strength is increasingly being linked to cash flow quality, earnings visibility and operational delivery. The Australian sto...
Highlights Profitable growth is reshaping how the market evaluates growth-focused companies across Australia. Pro Medicus (ASX:PME), Telix Pharmaceuticals (ASX:TLX) and Life360 (ASX:360) are drawing attention as investors focus on execution and business quality. Inflation trends, sector rotation and company-specific catalysts are creating a more selective environment for growth stocks. The Australian share market is entering a period where broad market move...
Is EchoIQ the ASX's Hottest AI Medtech Stock After the Pro Medicus Bombshell? Kalkine
Pro Medicus (ASX:PME) Signs Echo IQ Agreement: What It Means for PME Investors Kalkine
Shares in the AI-enabled heart imager have vaulted up to 50%, on the back of a $10-20 million investment from ... Read More The post Health Check: For Pro Medicus, lightning strikes twice on another ASX-listed imaging up and comer appeared first on Stockhead.
Highlights Pro Medicus has announced a strategic agreement with Echo IQ to support the expansion of artificial intelligence capabilities in medical imaging. The agreement combines a capital management initiative with a commercial distribution arrangement for AI-powered cardiac software. The latest development highlights the company's broader strategy of expanding its healthcare technology ecosystem. Australia's healthcare technology sector continues evolving a...
Pro Medicus (ASX:PME) writes a A$20m cheque into Echo IQ Stocks Down Under
Pro Medicus has signed a binding agreement with Echo IQ to boost its AI-driven cardiology solutions and expand commercial opportunities. The post Pro Medicus signs Echo IQ deal to boost AI cardiology offering appeared first on The Motley Fool Australia.
other announcement
Highlights Medical imaging software contracts are becoming a key measure for assessing healthcare sector momentum amid shifting market conditions. Pro Medicus (ASX:PME), CSL (ASX:CSL) and Cochlear (ASX:COH) highlight how execution, cash flow quality and market expectations are driving stock-specific narratives. US contract wins and index-related fund flows are increasingly influencing how healthcare stocks are being interpreted across the Australian market. Th...
Highlights Founder and insider alignment is becoming a key measure for assessing growth companies in a more selective market environment. Pro Medicus (ASX:PME), Life360 (ASX:360) and Lovisa Holdings (ASX:LOV) highlight how execution, cash flow quality and governance are shaping market sentiment. Growth companies are increasingly being judged on evidence of sustainable expansion rather than broad sector themes. The Australian share market is entering a phase wh...
Highlights Growth stocks are increasingly being judged on margin strength and cash-flow quality rather than revenue growth alone. Pro Medicus (ASX:PME), Life360 (ASX:360) and Lovisa Holdings (ASX:LOV) highlight how execution is shaping market attention across different sectors. Rising macro uncertainty and selective market sentiment are making profitable growth one of the most closely watched themes in Australian equities. The Australian share market is ent...
Pro Medicus (ASX:PME) Is Up 5.4% After Record Half-Year And A$280m Contracts Has The Bull Case Changed? simplywall.st
Highlights Specialist imaging and radiopharmaceutical businesses are attracting renewed attention across the Australian healthcare sector. Pro Medicus (ASX:PME), Telix Pharmaceuticals (ASX:TLX) and Cochlear (ASX:COH) remain key names linked to clinical adoption and healthcare technology trends. Market focus is shifting towards operating performance, contract quality, cash generation and sustainable growth signals. Australia's equity market is navigating a complex backdrop of geopolitical unce...
Pro Medicus (ASX:PME): The Premium ASX Tech-Healthcare Stock Everyone Watches Kalkine
Highlights A modest starting amount can provide exposure to global markets, healthcare technology and diversified Australian businesses. Pro Medicus, Wesfarmers and the iShares S&P 500 ETF each offer access to different growth and resilience themes. Diversification and quality remain important considerations when building a portfolio over time. Pro Medicus, Wesfarmers and the iShares S&P 500 ETF provide different pathways to healthcare technology, diversified Australian businesses and...
Big rally fuels debate: hold, buy, or sell? The post Pro Medicus shares are flying 35% higher. Time to cash out? appeared first on The Motley Fool Australia.
Highlights Pro Medicus (ASX:PME) gains renewed attention after appearing on a Strong Buy themed ASX tech list. Debt-free balance sheet and strong cash position reinforce its financial resilience. Global expansion of its Visage imaging platform supports continued healthcare software demand. Pro Medicus (ASX:PME) remains in focus as a leading health-tech company, supported by a debt-free balance sheet and expanding global adoption of its medical imaging software. Australian healthcare tec...
Highlights Intuitive Surgical’s recent weakness has reignited discussion around healthcare technology business models. Companies with recurring revenue streams continue attracting attention amid evolving healthcare trends. Australian healthcare leaders such as Pro Medicus, ResMed and Nanosonics remain closely watched for their scalable business models. Healthcare technology companies remain in focus as recurring revenue models, digital healthcare adoption and artificial intelligence con...
Is Pro Medicus (ASX:PME) Worth Adding to Your Watchlist? Kalkine
Highlights Growth stocks are facing a tougher quality test as investors focus on earnings upgrades and pricing power. Pro Medicus, REA Group, and ResMed are emerging as key reference points across the growth sector. Balance-sheet strength and operational execution are becoming more important than broad market enthusiasm. Australian growth stocks are facing a more demanding quality test as earnings upgrades, pricing power, and operational execution become increasingly important drivers o...
Pro Medicus (ASX:PME) Shares Valuation After S&P/ASX 50 Removal And Recent Contract Renewals simplywall.st
Should Visage 7 AI‑Optimized Reporting Rollout Shape Pro Medicus’ (ASX:PME) Long‑Term Imaging Edge? simplywall.st
The company was swept up in the huge sector-wide downturn in late 2025 and early 2026 as investors turned their backs on ASX healthcare shares. The post Is it time to get greedy with Pro Medicus shares? appeared first on The Motley Fool Australia.
PME, TNE, WTC, XRO, is it finally time to buy ASX tech stocks? Plus, base metals prices are soaring while lithium is teetering TradingView
other announcement
other announcement
other announcement
other announcement
PME, WTC, TNE — the SaaSpocalypse decoded: what killed ASX growth stocks, and what comes next Livewire Markets
other announcement
other announcement
Highlights Pro Medicus and James Hardie operate across healthcare technology and building materials within major ASX indices. Business models reflect sector-specific demand drivers, including digital imaging and fibre cement solutions. Operational updates, project pipelines, and global footprint remain central to ongoing developments. Overview of Pro Medicus and James Hardie across healthcare and materials sectors, highlighting operations, global presence, and their role within key ASX ...
Highlights PME valuation signals shaping healthcare tech outlook ASX indices reflecting evolving market sentiment Structural growth themes influencing Australian equities The short selling sector is often used as a behavioural indicator of market sentiment, reflecting how participants assess valuation strength, earnings stability, and broader structural expectations across equities. Within this evolving landscape, Pro Medicus Limited (ASX:PME), a leading healthcare imaging technology company ...
PME and JHX shares: 2 ASX shares to watch Rask Media
other announcement
director_dealing announcement
director_dealing announcement
director_dealing announcement
director_dealing announcement
director_dealing announcement
director_dealing announcement
director_dealing announcement
Kalkine
Motley Fool
Google News
Stockhead
Small Caps
ASX